SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.72
+6.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 90.5M | — | — | 886.0K | 2.3M |
| Cost of Revenue | 90.5M | 171.7M | — | — | — |
| Gross Profit | — | (171.7M) | — | 886.0K | 2.3M |
| Operating Expenses | |||||
| R&D Expense | 215.8M | 171.7M | 162.8M | 89.5M | 58.6M |
| SG&A Expense | 55.5M | 47.9M | 45.8M | 39.9M | 28.5M |
| General & Admin Expense | 55.5M | 47.9M | 45.8M | 39.9M | 28.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (70.0M) | (181.7M) | — | 113.7M | — |
| Total Operating Expenses | 201.3M | 37.9M | 208.6M | 243.2M | 87.1M |
| Cost and Expenses | 291.8M | 209.6M | 208.6M | 243.2M | 87.1M |
| Operating Income (EBIT) | (201.3M) | (209.6M) | (208.6M) | (242.3M) | (84.8M) |
| Non-Operating | |||||
| Interest Income | 29.6M | 24.9M | 21.3M | 6.1M | 837.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 29.6M | 24.9M | 21.3M | 6.1M | 837.0K |
| Other Non-Op Income/Expense | 22.4M | 54.3M | 599.0K | (96.5M) | 830.0K |
| Non-Operating Income (excl Interest) | (15.8M) | 10.0M | (599.0K) | (113.7M) | (830.0K) |
| EBT (Pre-Tax Income) | (178.9M) | (155.2M) | (208.0M) | (338.8M) | (84.0M) |
| Income Tax Expense | — | (15.0K) | 51.0K | (26.0K) | (136.0K) |
| Bottom Line | |||||
| Net Income | (178.9M) | (155.2M) | (208.0M) | (338.8M) | (83.8M) |
| Earnings from Cont. Ops | (178.9M) | (155.2M) | (208.0M) | (338.8M) | (83.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (178.9M) | (126.5M) | (149.6M) | (94.9M) | (83.8M) |
| Per Share | |||||
| Basic EPS | ($1.95) | ($1.98) | ($3.18) | ($46.15) | ($24.86) |
| Diluted EPS | ($1.95) | ($1.98) | ($3.18) | ($46.15) | ($24.86) |
| Revenue Per Share | $1.07 | $0.00 | $0.00 | $0.13 | $0.69 |
| Shares | |||||
| Basic Shares Outstanding | 84.7M | 64.1M | 47.0M | 6.9M | 3.4M |
| Diluted Shares Outstanding | 84.7M | 64.1M | 47.0M | 6.9M | 3.4M |
| Profitability Metrics | |||||
| EBITDA | (185.6M) | (209.6M) | (208.0M) | (127.8M) | (82.0M) |
| D&A | — | 10.0M | — | 744.0K | 2.0M |
| EBIT | (185.6M) | (219.6M) | (208.0M) | (128.6M) | (84.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026